Author

D. Challis

Institutions: The University of Melbourne, Monash Medical Centre, Royal Hobart Hospital

Observed institutions: Garvan Institute of Medical Research, The University of Melbourne, University of Utah, Huntsman Cancer Institute, Monash Medical Centre, Royal Hobart Hospital, UNSW Sydney

ORCID: 0000-0001-8193-120X

Observed ORCID: 0000-0001-8193-120X

OpenAlex ID: A5049972008

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

2018 · Olga Kondrashova, Monique Topp, et al. · Nature Communications · 296

Prognostic gene expression signature for high-grade serous ovarian cancer

2020 · J. Millstein, T. Budden, et al. · Annals of Oncology · 155

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

2020 · Eun Young Kang, Dane Cheasley, et al. · Modern Pathology · 42

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance

2024 · Ksenija Nesic, John J. Krais, et al. · Molecular Cancer · 36

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

2018 · Matthew S. Block, Robert A. Vierkant, et al. · Mayo Clinic Proceedings · 31

Timing of whole genome duplication is associated with tumor-specific MHC-II depletion in serous ovarian cancer

2024 · Nikki L. Burdett, Madelynne O. Willis, et al. · Nature Communications · 16

Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer

2023 · Nikki L. Burdett, Madelynne O. Willis, et al. · Scientific Reports · 6

Works count: 7

Citation count: 581

H-index: 6

I10-index: 6